IGC Pharma (IGC) Receivables (2011 - 2026)
IGC Pharma (IGC) reported Receivables of $694000.0 for Q1 2026, down 2.8% year-over-year from $714000.0 in Q1 2025, and up 2.21% quarter-over-quarter from $679000.0 in Q4 2025.
IGC Pharma (IGC) Receivables (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has 16 years of Receivables data on file, last reported at $694000.0 in Q1 2026.
- Receivables for Q1 2026 came in at $694000.0, down 2.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $694000.0 (down 2.8% YoY), and the FY2026 annual result was $694000.0, down 2.8% from the prior year.
- Receivables improved to $694000.0 in Q1 2026 per IGC's latest filing, from $679000.0 in the prior quarter.
- Over five years, Receivables peaked at $1.2 million in Q2 2023 and troughed at $493000.0 in Q1 2022.
- A 5-year average of $809000.0 and a median of $728000.0 in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2023 and 2024: Receivables surged 134.73% in 2023, then sank 39.29% in 2024.
- A 5-year view of Receivables shows it stood at $1.0 million in 2022, then increased by 3.59% to $1.0 million in 2023, then dropped by 29.87% to $728000.0 in 2024, then decreased by 6.73% to $679000.0 in 2025, then grew by 2.21% to $694000.0 in 2026.
- Business Quant data shows IGC's Receivables at $694000.0 in Q1 2026, $679000.0 in Q4 2025, and $711000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | 694,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 694,000.00 |
| Dec 31, 2025 | 679,000.00 |
| Sep 30, 2025 | 711,000.00 |
| Jun 30, 2025 | 767,000.00 |
| Mar 31, 2025 | 714,000.00 |
| Dec 31, 2024 | 728,000.00 |
| Sep 30, 2024 | 729,000.00 |
| Jun 30, 2024 | 714,000.00 |
| Mar 31, 2024 | 725,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 940,000.00 |
| Jun 30, 2022 | 501,000.00 |
| Mar 31, 2022 | 493,000.00 |
| Dec 31, 2021 | 546,000.00 |
| Sep 30, 2021 | 514,000.00 |
| Jun 30, 2021 | 537,000.00 |